UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders

Pharmacological reviews, 2022-07, Vol.74 (3), p.600-629

2022

Volltextzugriff (PDF)

Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders

Biochimica et biophysica acta. Proteins and proteomics, 2020-08, Vol.1868 (8), p.140428-140428, Article 140428

2020

Volltextzugriff (PDF)

Cathepsin B inhibition blocks neurite outgrowth in cultured neurons by regulating lysosomal trafficking and remodeling

Journal of neurochemistry, 2020-11, Vol.155 (3), p.300-312

2020

Volltextzugriff (PDF)

The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury

Journal of neurotrauma, 2014-03, Vol.31 (5), p.515

2014

Volltextzugriff (PDF)

Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate

Frontiers in neurology, 2015-09, Vol.6, p.178-178

2015

Volltextzugriff (PDF)

Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions

ACS chemical biology, 2021-09, Vol.16 (9), p.1628-1643

2021

Volltextzugriff (PDF)

Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease

Biochimica et biophysica acta, 2012-01, Vol.1824 (1), p.89-104

2012

Volltextzugriff (PDF)

Penetrating Traumatic Brain Injury Triggers Dysregulation of Cathepsin B Protein Levels Independent of Cysteine Protease Activity in Brain and Cerebral Spinal Fluid

Journal of neurotrauma, 2020-07, Vol.37 (13), p.1574

2020

Volltextzugriff (PDF)

Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence

Journal of Alzheimer's disease, 2012-01, Vol.29 (4), p.827

2012

Volltextzugriff (PDF)

Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid-β in hAβPP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition

Journal of Alzheimer's disease, 2023-01, Vol.93 (1), p.33

2023

Volltextzugriff (PDF)

The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity

Journal of Alzheimer's disease, 2011-01, Vol.26 (2), p.387

2011

Volltextzugriff (PDF)

Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic

Journal of Alzheimer's disease, 2014-01, Vol.41 (1), p.129

2014

Volltextzugriff (PDF)

Inhibitors of Cathepsin B Improve Memory and Reduce β-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, β-Secretase Site of the Amyloid Precursor Protein

The Journal of biological chemistry, 2008-03, Vol.283 (12), p.7745-7753

2008

Volltextzugriff (PDF)

Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce β-amyloid related to Alzheimer's disease

Biological chemistry, 2010-08, Vol.391 (8), p.861-872

2010

Volltextzugriff (PDF)

Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor protein

Biochemical and biophysical research communications, 2009-08, Vol.386 (2), p.284-288

2009

Volltextzugriff (PDF)

Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B

Biochemistry (Easton), 2022-02, Vol.61 (4), p.228-238

2022

Volltextzugriff (PDF)

The Short-Term Response of Soil Mesofauna Community Density and Diversity to Dryland Reclamation Practices in Boreal Forest Soils of Northern Alberta

Hook, Gregory

2019

Volltextzugriff (PDF)

Cysteine protease inhibitors effectively reduce in vivo levels of brain β-amyloid related to Alzheimer's disease

Biological chemistry, 2007-02, Vol.388 (2), p.247-252

2007

Volltextzugriff (PDF)

Alternative pathways for production of β-amyloid peptides of Alzheimer's disease

Biological chemistry, 2008-08, Vol.389 (8), p.993-1006

2008

Volltextzugriff (PDF)

Cysteine protease inhibitors reduce brain β-amyloid and β-secretase activity in vivo and are potential Alzheimer's disease therapeutics

Biological chemistry, 2007-09, Vol.388 (9), p.979-983

2007

Volltextzugriff (PDF)

Pharmacogenetic Features of Inhibitors to Cathepsin B that Improve Memory Deficit and Reduce Beta-Amyloid Related to Alzheimer’s Disease

Biological chemistry, 2010-08, Vol.391 (8), p.861-872

2010

Volltextzugriff (PDF)

Deletion of the Cathepsin B gene improves memory deficits in a Alzheimer's disease mouse model expressing APP containing the wild‐type β‐secretase site sequence

The FASEB journal, 2012-04, Vol.26 (S1)

2012

Volltextzugriff (PDF)

Inhibitors of Cathepsin B Improve Memory and Reduce Î²-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, Î²-Secretase Site of the Amyloid Precursor Protein

The Journal of biological chemistry, 2008-03, Vol.283 (12), p.7745

2008

Volltextzugriff (PDF)

Inhibitors of Cathepsin B Improve Memory and Reduce b-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, b-Secretase Site of the Amyloid Precursor Protein

The Journal of biological chemistry, 2008-03, Vol.283 (12), p.7745-7753

2008

Volltextzugriff (PDF)

Cysteine protease inhibitors effectively reduce in vivo levels of brain I2-amyloid related to Alzheimer's disease

Biological chemistry, 2007-02, Vol.388 (2), p.247-252

2007

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(98)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(112)
Japanisch
(19)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(66)
Life Sciences & Biomedicine
(55)
Humans
(32)
Animals
(25)
Biochemistry & Molecular Biology
(14)
Cathepsin B
(13)
Mice
(13)
Cathepsin B - Metabolism
(11)
Female
(11)
Male
(11)
Neurosciences & Neurology
(10)
Alzheimer Disease - Metabolism
(9)
Amyloid Beta-Peptides - Metabolism
(9)
Biological And Medical Sciences
(9)
Cathepsin B - Genetics
(9)
Disease Models, Animal
(9)
Neurosciences
(9)
Technology
(9)
Alzheimer's Disease
(8)
Cathepsin B - Antagonists & Inhibitors
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders

Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders

Cathepsin B inhibition blocks neurite outgrowth in cultured neurons by regulating lysosomal trafficking and remodeling

The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury

Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate

Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions

Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease

Penetrating Traumatic Brain Injury Triggers Dysregulation of Cathepsin B Protein Levels Independent of Cysteine Protease Activity in Brain and Cerebral Spinal Fluid

Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence

Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid-β in hAβPP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition

The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity

Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic

Inhibitors of Cathepsin B Improve Memory and Reduce β-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, β-Secretase Site of the Amyloid Precursor Protein

Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce β-amyloid related to Alzheimer's disease

Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor protein

Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B

The Short-Term Response of Soil Mesofauna Community Density and Diversity to Dryland Reclamation Practices in Boreal Forest Soils of Northern Alberta

Cysteine protease inhibitors effectively reduce in vivo levels of brain β-amyloid related to Alzheimer's disease

Alternative pathways for production of β-amyloid peptides of Alzheimer's disease

Cysteine protease inhibitors reduce brain β-amyloid and β-secretase activity in vivo and are potential Alzheimer's disease therapeutics

Pharmacogenetic Features of Inhibitors to Cathepsin B that Improve Memory Deficit and Reduce Beta-Amyloid Related to Alzheimer’s Disease

Deletion of the Cathepsin B gene improves memory deficits in a Alzheimer's disease mouse model expressing APP containing the wild‐type β‐secretase site sequence

Inhibitors of Cathepsin B Improve Memory and Reduce Î²-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, Î²-Secretase Site of the Amyloid Precursor Protein

Inhibitors of Cathepsin B Improve Memory and Reduce b-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, b-Secretase Site of the Amyloid Precursor Protein

Cysteine protease inhibitors effectively reduce in vivo levels of brain I2-amyloid related to Alzheimer's disease

Suchergebnisse filtern